Results 31 to 40 of about 6,944 (246)

Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong

Cardiovascular Diabetology, 2023
Background There are limited data on head-to-head comparative risk of stroke between sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA).
David Tak Wai Lui, Eric Ho Man Tang, Tingting Wu, Ivan Chi Ho Au, Chi Ho Lee, Yu Cho Woo, Kathryn Choon Beng Tan, Carlos King Ho Wong   +7 more
doaj   +1 more source

Combined Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Therapy to Restore Fertility in Patients With Obesity, Polycystic Ovary Syndrome, and Incident Type 2 Diabetes [PDF]

Cureus
Mainak Banerjee, Sujoy Dasgupta
openalex   +2 more sources

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background We investigated the effects of insulin, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their combination on vascular and cardiac function of patients with type 2 diabetes mellitus.
Ignatios Ikonomidis, George Pavlidis, John Thymis, Dionysia Birba, Aimilianos Kalogeris, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou, Konstantinos Katogiannis, George Dimitriadis, Aristotelis Bamias, Efstathios Iliodromitis, Vaia Lambadiari   +14 more
doaj   +1 more source

Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists

Pharmaceuticals, 2022
Glucagon-like peptide-1 (GLP-1) is easily degraded by dipeptidyl peptidase-4 (DPP-4) in the human body, limiting its therapeutic effect on type II diabetes.
Lei Sun, Zhi-Ming Zheng, Chang-Sheng Shao, Zhi-Yong Zhang, Ming-Wei Li, Li Wang, Han Wang, Gen-Hai Zhao, Peng Wang   +8 more
doaj   +1 more source

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study

Cardiovascular Diabetology, 2021
Aim We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiated GLP-1 receptor agonists (GLP-1RA) or basal insulin (BI) under routine care.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini   +5 more
doaj   +1 more source

Long-acting GLP-1RAs

JAAPA, 2020
ABSTRACT Over recent decades, an improved understanding of the pathophysiology of type 2 diabetes mellitus (T2DM) and glucose regulation has led to innovative research and new treatment paradigms. The discovery of the gut peptide glucagon-like peptide-1 (GLP-1) and its role in glucose regulation paved the way for the class of GLP-1 receptor ...
Ji Hyun, Chun, Amy, Butts
openaire   +4 more sources

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study

Cardiovascular Diabetology
Background Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients ...
Jasmine Melissa Madsen, Alexander Krüger Kjaer, Jacob Thomsen Lønborg, Lars Køber, Charlotte Glinge, Reza Jabbari, Thomas Engstrøm   +6 more
doaj   +1 more source

Impact of Perioperative Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Carpal Tunnel Release

Journal of Hand Surgery Global Online
Purpose: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use continues to rise because of its efficacy in glycemic control and weight reduction. There are sparse data on the implications of GLP-1RA therapy on surgical outcomes.
Nicholas C. Bank, MD, Stephen J. Perle, BS, Bradley J. Lauck, BA, Alecia J. Rajesh, BS, Alexander D. Jeffs, MD, Reid W. Draeger, MD   +5 more
doaj   +1 more source